

Matthew P. Smeltzer<sup>1</sup>; Leigh M. Boehmer<sup>2</sup>; Amanda Kramar<sup>2</sup>; Thomas M. Asfeldt<sup>3,4</sup>; Nicholas R. Faris<sup>5</sup>; Christine F. Amorosi<sup>6</sup>; Meredith A. Ray<sup>1</sup>; Vikki G. Nolan<sup>1</sup>; Randall A. Oyer<sup>7</sup>; Christopher S. Lathan<sup>8,9</sup>; Raymond U. Osarogiabon<sup>5</sup>

<sup>1</sup>Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, The University of Memphis, Memphis, TN, USA; <sup>2</sup>Association of Community Cancer Centers, Rockville, MD, USA; <sup>3</sup>Sanford USD Medical Center, Sioux Falls, SD, USA; <sup>4</sup>Sanford Health Cancer Center, Worthington, MN, USA; <sup>5</sup>Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA; <sup>6</sup>Health Quality Solutions, Arlington, VA, USA; <sup>7</sup>Ann B. Barshinger Cancer Institute, Penn Medicine Lancaster General Health, Lancaster, PA, USA; <sup>8</sup>Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Boston, MA, USA; <sup>9</sup>Harvard Medical School, Boston, MA, USA

**Supplementary Table 1: Patient demographics and baseline clinical characteristics aggregated across all testing sites by Medicaid/dual-eligible vs. non-Medicaid payer status (N=926)**

Characteristic, %	Medicaid/dual-eligible n=257	Non-Medicaid* n=669	P value
Sex			
Female	48.2	51.6	
Male	51.8	48.4	0.3655 <sup>††</sup>
Age group			
<90 years	99.6	98.1	
≥90 years	0.4	1.9	0.1289 <sup>§</sup>
Race			
Caucasian	68.8	88.8	
Black or African American	8.2	2.8	
Other <sup>†</sup> /not reported	23.0	8.4	<0.0001 <sup>††</sup>
Missing=2			
Ethnicity			
Hispanic/Latino	3.5	1.8	
Not Hispanic/not Latino	81.3	90.9	
Not reported	15.2	7.3	0.0003 <sup>††</sup>
Employment status			
Currently employed	14.4	21.5	
Retired	26.1	51.9	
Unemployed	33.9	8.5	
Unknown	25.7	18.1	<0.0001 <sup>††</sup>
Median (range) age at diagnosis (years)	61 (39, 88)	70 (39, 89)	<0.0001 <sup>†</sup>
Smoking status			
Active	47.5	28.6	
Former	44.0	59.8	
Never	7.4	7.9	
Not reported	1.2	3.7	<0.0001 <sup>††</sup>
Type of smoking: cigarettes			
Yes	80.9	70.5	
No	19.1	29.5	0.0014 <sup>††</sup>
Median (range) duration of smoking (years)	40 (2, 67)	40 (3, 69)	0.8927 <sup>†</sup>
Median (range) pack-years	44 (4, 220)	40 (1, 240)	0.5577 <sup>†</sup>
Median (range) number of comorbidities	2 (0, 6)	2 (0, 5)	0.0115 <sup>†</sup>
Patients with any prior cancer(s)			
Yes	87.2	78.9	
No	12.8	21.1	0.0041 <sup>††</sup>
Aggregate staging			
Stage 0	0.4	0.3	
Stage I–IIA	23.7	23.6	
Stage IIB	7.0	6.1	
Stage IIIA	9.7	10.2	
Stage IIIB–C	7.0	5.1	
Stage IV	28.0	21.7	
Insufficient/not reported	24.1	33.0	0.1456 <sup>††</sup>

Column percentages may not add up to 100.0% because of rounding. Statistical significance was assessed at an alpha level of 0.05, without adjustments for multiple comparisons (Rothman KJ. *Epidemiology* 1990;1:43-46.).

\*Commercial insurance, Medicare only, military insurance, none, or self-pay

<sup>†</sup>Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Other, and Unknown

<sup>††</sup>P value based on chi-square test


<sup>§</sup>P value based on Fisher's exact test

<sup>†††</sup>P value based on median 1-way analysis

• Most frequently selected beta OCCM assessment areas

- Prospective multidisciplinary case planning (3 testing sites): Different formats of multidisciplinary case discussion, such as traditional biweekly (in-person) tumor board, virtual tumor board, and multidisciplinary team huddle, were used

**Supplementary Figure 1: Select quality metrics for the different formats of prospective multidisciplinary case planning**



Data in panel B are first quartile, median, and third quartile.

○ Patient access to care, including timeliness of care (2 testing sites)

At 1 testing site, median time from detection of a suspicious lesion to positive diagnosis was **16** (6, 26) days for Medicaid/dual-eligible patients vs. **18.5** (8.5, 44.5) days for commercially insured patients (P=0.68)

○ Tobacco cessation, including evaluation of use (2 testing sites)

At a testing site offering cessation services with program referrals, **55.6%** (10/18) of active smokers among Medicaid/dual-eligible patients expressed readiness to quit compared with **43.2%** (16/37) of active smokers among all patients

At a testing site offering the Freedom from Smoking<sup>®</sup> program, **54.5%** (6/11) of active smokers among Medicaid/dual-eligible patients expressed readiness to quit compared with **21.3%** (10/47) of active smokers among all patients

## ACKNOWLEDGMENTS

- Advisory Committee: Thomas M. Asfeldt; Becky DeKay; Andrea Ferris; Lovell Jones; Christopher S. Lathan (Co-PI); Matthew J. Loscalzo; James Mulshine; Kathleen Nolan; Randall A. Oyer (Co-PI); Shawn M. Regis; Maureen Rigney; Cardinale B. Smith; and Mark S. Soberman
- Technical Expert Panel: Thomas M. Asfeldt (Chair); Karyl Blaseg; Richard Deming; and Nancy Johnson
- Lead Clinical Research Consultant: Raymond U. Osarogiabon
- Data analysis: Meredith A. Ray; Vikki G. Nolan; and Nicholas R. Faris
- Testing sites: AdventHealth Daytona Beach (formerly Florida Hospital Memorial Medical Center), Florida; Advocate Lutheran General Hospital, Lutheran General Cancer Institute, Illinois; Ascension Wheaton Memorial Medical Center, Wisconsin; Cowell Family Cancer Center, Michigan; Genesis Cancer Care Center, Ohio; Northwest Medical Specialties, Washington; and Southern Ohio Medical Center, Ohio